Research into the safety and efficacy of combining SGLT2 inhibitors with other diabetes medications, such as GLP-1 receptor agonists, insulin, and traditional oral agents, can provide insights into optimal combination strategies. The gene discussed is SLC5A2; the disease is diabetes mellitus.